---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-26-000048"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2026-08-03T20:02:02+00:00"
generated_at: "2026-08-03T20:03:09.052710+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics Q2 2026 net loss $28.7M; initiates Phase 2 DMD trial for rinvatercept

## Summary
- Net loss of $28.7M in Q2 2026 vs $30.7M in Q2 2025; R&D expenses down to $22.3M from $43.5M.
- Cash and cash equivalents $257.6M as of June 30, 2026; expected to fund operations into first half 2028.
- Initiated Phase 2 clinical trial of rinvatercept in Duchenne muscular dystrophy; initial data expected first half 2027.
- General and administrative expenses decreased to $8.6M from $14.5M due to restructuring and lower professional fees.

## SEC filing metadata
- accession: 0001664710-26-000048
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2026-08-03T20:02:02+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000048/0001664710-26-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000048/kros-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-26-000048
- JSON: https://secwatch.observer/filing/0001664710-26-000048.json
- Plain text: https://secwatch.observer/filing/0001664710-26-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.